Experimental hepatitis b drug shows promise in lowering virus markers

NCT ID NCT02604199

Terminated Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 14, 2026 · Last updated May 25, 2026 · Updated 22 times

Summary

This study tested an experimental drug called ARC-520 in adults with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could further reduce hepatitis B surface antigen levels in the blood. The trial was stopped early, but results may help guide future treatments for this long-term liver infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site 1

Hong Kong, 999077, China
Research Site 10

Leipzig, 04103, Germany
Research Site 11

Frankfurt, 60590, Germany
Research Site 12

Yangsan-si Gyeongnam, 626-770, South Korea
Research Site 13

Busan, 602-739, South Korea
Research Site 14

Seoul, 110-744, South Korea
Research Site 15

Incheon, 405-760, South Korea
Research Site 16

Seoul, 120-752, South Korea
Research Site 2

Hong Kong, China
Research Site 3

Tübingen, 72076, Germany
Research Site 4

Leipzig, 4103, Germany
Research Site 5

München, 81377, Germany
Research Site 6

Ulm, 89081, Germany
Research Site 7

Würzburg, 97080, Germany
Research Site 8

Hanover, 30625, Germany
Research Site 9

Hamburg, 20099, Germany

Conditions

Explore the condition pages connected to this study.

HEPATITIS B